Aim: To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency.
increased in those with type 2 diabetes ≥65 years of age, among whom 43% have moderate or severe renal insufficiency and 48% have mild renal insufficiency. 1 While it is widely recognized that the choice of an antihyperglycaemic agent (AHA) for treatment of type 2 diabetes should be influenced by renal function, only CKD stages 3-5 are usually considered relevant to that decision. 2 Additionally, clinical studies in patients with CKD are usually focused on patients with eGFR <60 mL/min/1.73m 2 . While patients with type 2 diabetes and mild renal insufficiency are typically included in Phase III studies of antihyperglycaemic therapies, the specific impact of mild renal insufficiency on the efficacy and safety of most AHAs has not generally been prospectively evaluated in clinical trials.
Among the classes of oral AHAs available for treatment of type 2 diabetes, dipeptidyl peptidase-4 (DPP-4) inhibitors are considered both efficacious and well tolerated across the range of renal function, although dose adjustment to control drug exposure is sometimes required. 3 In contrast, the sodium/glucose transporter-2 (SGLT-2) inhibitors have reduced efficacy in patients with moderate to severe renal insufficiency due to their mechanism of action. 4 The CompoSIT-R (comparison of sitagliptin with dapagliflozin in mild renal impairment) study was a prospective, randomized clinical trial comparing the efficacy and safety of the DPP-4 inhibitor sitagliptin with the SGLT-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. ). Eligible patients were on a stable dose of metformin (≥1500 mg/d) alone or in combination with a sulfonylurea (SU) (at a dose of ≥50% of the maximum labelled dose in the country of the investigational site) for ≥8 weeks, with an HbA1c ≥7.0% and ≤9.5% (≥53 mmol/mol to ≤80 mmol/mol) at screening, and a fasting finger-stick glucose >6.1 mmol/L and <14.4 mmol/L at randomization.
| METHODS

| Participants
Patients were excluded from the study if they had type 1 diabetes, a history of ketoacidosis, active liver disease, significant cardiovascular disease, malignancy or haematological disorders, or if, in the opinion of the investigator, they were at high risk for volume depletion, hypotension and/or electrolyte imbalances. Patients were also excluded if they had been previously treated with any AHAs other than metformin or, if on dual therapy, metformin in combination with an SU, within 12 weeks prior to screening. Laboratory exclusion criteria included serum alanine aminotransferase or aspartate aminotransferase levels >2 times the upper limit of normal (ULN), haemoglobin <120 g/L (male) or <110 g/L (female), triglycerides >6.8 mmol/L or thyroid-stimulating hormone outside the central laboratory normal range.
Written informed consent was obtained from all study participants.
| Study design
This was a multinational, randomized, double-blind, active comparator-controlled, parallel-group trial, including a 2-week screening period, a 2-week single-blind placebo run-in period, a 24-week double-blind treatment period and a post-treatment telephone or inperson contact 14 days after the last dose of blinded study drug (Figure 1 ).
After the run-in period, patients were randomized centrally using an interactive voice response system, in 
| Study evaluations
The primary objectives of this study were: (i) after 24 weeks, to assess the effect of the addition of sitagliptin compared with the addition of dapagliflozin on HbA1c; and (ii) over 24 weeks, to assess the overall safety and tolerability of sitagliptin in comparison to that of dapagliflozin. The primary study hypothesis was that after 24 weeks, the change from baseline in HbA1c in subjects treated with the addition of sitagliptin is non-inferior to that in subjects treated with the addition of dapagliflozin. 
| Efficacy endpoints
Glycaemic efficacy endpoints were change from baseline in HbA1c, 2-hour incremental PPGE, 2-hour PPG, FPG, postprandial insulin, glucagon, and insulin:glucagon ratio at Week 24, and proportion of patients who achieved an HbA1c goal of <7% (<53 mmol/mol) at Week 24.
| Safety endpoints
Safety endpoints were incidences of adverse events (AEs), percentages of patients meeting predefined limits of change (PDLC) in laboratory parameters, and change from baseline at Week 24 in laboratory parameters, vital signs and body weight. AEs of hypoglycaemia, documented hypoglycaemia and severe hypoglycaemia were predefined AEs of interest. In subjects completing the clinical trial on study medication, safety data were collected from the initiation of treatment until 2 weeks after discontinuation of treatment. For subjects who discontinued study medication prematurely, safety data were collected from the initiation of treatment until Week 24. • ≥ 25years of age with type 2 diabetes and eGFR ≥60 and <90 mL/min/1.73m 2 and on • Metformin ≥1500 mg/day for ≥8 weeks with HbA1c ≥7.0 and ≤9.5% or on • Metformin ≥1500 mg/day + an SU (at a dose of ≥50% of maximum labelled dose) with HbA1c ≥7.0 and ≤9.5%
| Statistical analyses
At Visit 2/Week -2:
• eGFR ≥60 and <90 mL/min/1.73m 2 and • ≤20 mL/min/1.73m 2 2 The interval between Visit 1 and Visit 2 for eligible subjects was to be at least 2 weeks and no more than approximately 6 weeks. 3 Subjects entering the study on metformin remained on a stable dose of metformin; subjects entering on metformin + an SU remained on stable doses of both agents between-group rate differences computed using the Miettinen and Nurminen method. 7 For this analysis, multiple imputations of missing A sample size of 278 participants per treatment group was estimated to provide >99% power to establish that sitagliptin is noninferior to dapagliflozin in lowering HbA1c at an overall one-sided, 2.5% α-level, assuming an underlying treatment difference of 0%, and 90% power to demonstrate the superiority of sitagliptin versus dapagliflozin in lowering HbA1c at an overall one-sided, 2.5% α-level, if the underlying treatment difference in HbA1c is −0.2%.
The study-wise type I error rate was controlled using an ordered testing procedure. First, non-inferiority of sitagliptin compared with dapagliflozin for change from baseline in Hba1c was tested. When the success criterion for non-inferiority was met, superiority was assessed. When the test for superiority was successful, the secondary hypothesis for postprandial glucose excursion was tested. All three tests were conducted at α = 0.025 (one-sided).
3 | RESULTS
| Patient disposition and characteristics and dapagliflozin doses
The study was conducted at 185 sites in 24 countries (a list of participating investigators can be found in Table S1 ). A total of 2770 patients were screened and 614 were randomized, 307 to sitagliptin and 307 to dapagliflozin. The study was initiated on October 21, 2015 and completed on October 10, 2017. Of the 614 randomized patients, 595 (96.9%) completed the study, and 494 (80.5%) completed on study medication (Table S2) . One patient in the dapagliflozin group, associated with a protocol violation, was randomized but did not take a dose of study medication; this patient was included in the population of randomized patients for the disposition table but was excluded from all efficacy and safety analyses.
Baseline demographics and clinical parameters were similar between the treatment groups ( At Week 24, there were no significant between-group differences in changes from baseline in LS mean 2-hour incremental PPGE, 2-hour PPG, FPG, or in changes from baseline in postmeal glucagon AUC 0-120 , insulin AUC 0-120, or the ratio of insulin AUC 0-120 to glucagon AUC 0-120 (Table 2) .
| Efficacy
Throughout the trial (the 24-week treatment period plus the 2-week safety follow-up period), a lower percentage of patients in the sitagliptin group had one or more telephone contacts associated with personal health concerns (not study-scheduled contacts) compared with the dapagliflozin group (6.8% vs. 11.8%, respectively). The total number of telephone contacts was also lower in the sitagliptin group than in the dapagliflozin group (30 vs. 58, respectively). The percentage of patients with one or more in-person visits associated with personal health concerns (not scheduled study visits) was similar in the sitagliptin and dapagliflozin groups (35.2% and 35.6%, respectively); the total number of in-person visits was 247 in the sitagliptin group and 272 in the dapagliflozin group.
| Safety and tolerability
During the study, 48.9% of patients in the sitagliptin group experienced one or more AEs compared with 51.6% in the dapagliflozin group. No patients died. With the exception of drug-related AEs (7.8% in the sitagliptin group and 13.7% in the dapagliflozin group, Change Table 3 ).
The incidences of AEs and of specific AEs by system organ class (SOC) reported for ≥4 patients in at least one treatment group were generally similar between the treatment groups (Table S4 ). Infections and infestations was the only SOC in which the 95% CI for the between-group difference in incidence excluded 0; in this SOC the incidence of AEs was higher in the dapagliflozin group (n = 66 The incidences of patients with documented symptomatic hypoglycaemia, severe hypoglycaemia and asymptomatic hypoglycaemia were similar between the two treatment groups (Table 3 ). There were higher incidences of patients with AEs of hypoglycaemia in the population whose background medication included an SU (15.8% and a Difference in % vs. dapagliflozin; estimate (95% CI) was computed only for AE summary and hypoglycaemia endpoints with at least 4 patients having events in one or more treatment groups. b Assessed by the investigator as related to study drug. c Symptomatic hypoglycaemia: episode with clinical symptoms attributed to hypoglycaemia, without regard to glucose level. d Documented symptomatic hypoglycaemia: episode with clinical symptoms attributed to hypoglycaemia with a documented glucose level of ≤3.9 mmol/L (≤70 mg/dL). e Severe hypoglycaemia: episode that required assistance, either medical or non-medical. Episodes with a markedly depressed level of consciousness, a loss of consciousness, or seizure were classified as having required medical assistance, whether or not medical assistance was obtained. f Asymptomatic hypoglycaemia: finger-stick glucose values ≤3.9 mmol/L (≤70 mg/dL) without symptoms.
16.0% in the sitagliptin and dapagliflozin groups, respectively) compared with the population not using an SU (3.3% and 3.6% in the sitagliptin and dapagliflozin groups, respectively) ( Table 3 ).
There was a lower incidence of genital mycotic infection-related AEs in the sitagliptin group compared with the dapagliflozin group in both men (0.6% vs. 4.3%, respectively) and women (0.0% vs. 5.0%, respectively). The incidences of volume depletion events were low in both groups (0.7% and 1.3% in the sitagliptin and dapagliflozin groups, respectively). The proportions of participants who met PDLC criteria for laboratory parameters were similar between the sitagliptin and dapagliflozin groups, and no clinically meaningful between-group differences were observed. The proportion of participants with at least one eGFR decrease from baseline >30% was similar between the sitagliptin and dapagliflozin groups (4.3% and 5.6%, respectively), while three participants (1.0%) in the sitagliptin group and none in the dapagliflozin group had at least one eGFR decrease from baseline >50%.
Greater decreases from baseline in mean systolic blood pressure and body weight were observed in the dapagliflozin group than in the sitagliptin group through Week 24 ( Figure S1 ).
| DISCUSSION
In the clinical trial described here, in subjects with type 2 diabetes and mild renal insufficiency, sitagliptin improved glycaemic control to a greater extent than dapagliflozin. These data provide clinical trial evidence that can inform patient-centered decisions for the treatment of patients with type 2 diabetes and mild renal insufficiency. The overall prevalence of patients with type 2 diabetes and mild renal insufficiency is estimated to be nearly 40% and prevalence increases with age (estimated to be nearly 50% in patients with type 2 diabetes ≥65 years of age). 1 Improved glycaemic control has been shown to reduce the risk of diabetic complications and to slow progression of renal impairment. 10 While metformin is the standard first-line pharmacologic intervention for the management of hyperglycaemia in type 2 diabetes, additional therapies, including oral agents such as an SU, a DPP-4 inhibitor, or an SGLT-2 inhibitor are often prescribed in patients with mild renal insufficiency to achieve glycaemic control. This paper provides data on the efficacy and safety of sitagliptin and dapagliflozin, in combination with other commonly used AHAs, in patients with type 2 diabetes and mild renal insufficiency.
DPP-4 inhibitors are often used in patients with type 2 diabetes and renal disease because these agents maintain efficacy and demonstrate good tolerability across the spectrum of renal disease. 3 On the other hand, the efficacy of SGLT-2 inhibitors is reduced in patients with moderate renal insufficiency and is contraindicated in patients with severe renal insufficiency. 11 These clinical observations are consistent with the distinct mechanisms of action of the two classes of agents. DPP-4 inhibitors stabilize the incretins GLP-1 and GIP, two peptides which stimulate the release of insulin in a glucose-dependent manner, 12 while the mechanism of action of SGLT-2 inhibitors depends on renal function. 13 However, until now, these two classes of AHAs have not been prospectively evaluated in a study limited to a population of patients with mild renal insufficiency.
In the current study, 24 weeks of treatment with the DPP-4
inhibitor sitagliptin was associated with greater reduction from baseline in HbA1c compared with the SGLT-2 inhibitor dapagliflozin; in addition, after 24 weeks, more patients met the HbA1c goal of <7% with sitagliptin than with dapagliflozin. Both treatments resulted in reductions from baseline in the 2-hour incremental PPGE and 2-hour PPG. While the reductions with sitagliptin were slightly larger than with dapagliflozin for both of these postprandial glycaemic endpoints, there were no significant between-group differences in these parameters.
Both treatments were generally well tolerated. The treatment groups had similarly low rates of hypoglycaemia when the background medication was metformin alone. When the background medication included a sulfonylurea, the rates of hypoglycaemia were higher and similar in both groups, as expected due to the influence of this class of agent. [14] [15] [16] With regard to the small increase in the observed incidences of abdominal pain and vomiting with sitagliptin compared with dapagliflozin, and of edema peripheral with dapagliflozin compared with sitagliptin, imbalances of this type have not previously been noted in pooled safety analyses of either treatment. 17, 18 Overall, the incidence of drug-related AEs was higher in the dapagliflozin group than in the sitagliptin group. Most of the drug-related
AEs that occurred at a higher observed incidence with dapagliflozin compared with sitagliptin were in categories of events that have been associated with SGLT-2 inhibitor treatment, in particular, genital mycotic infections. 19 The increased risk of genital mycotic infections is typical of the class of SGLT-2 inhibitors and is likely to be related to the mechanism of action of the class, which results in increased glycosuria. Other between-group differences observed were related to blood pressure and body weight. Greater mean decreases from baseline in systolic blood pressure and body weight were observed in the dapagliflozin group than in the sitagliptin group, as expected with SGLT-2 inhibitors. 20 No meaningful changes from baseline in mean blood pressure or body weight were observed in the sitagliptin group.
The results of this clinical trial may be of particular interest to physicians treating older patients with type 2 diabetes. Age is associated with reduction in renal function, 21 and together with potentially longer duration of diabetes, older patients are likely to be at increased risk of microvascular complications 22 including renal impairment and other co-morbidities. 23 A limitation of this study is that the results are relevant to the population studied and not necessarily to patients at other stages of CKD. Another limitation is that the study evaluated sitagliptin and dapagliflozin, and results cannot be extrapolated to other DPP-4 or SGLT-2 inhibitors. The strengths of this study are: its large sample size, which allowed a robust estimate of between-group differences in efficacy; the requirement for duplicate eGFR measurements during screening that ensured a population with stable renal status; and uptitration of dapagliflozin to its maximal approved dose (achieved in approximately 95% of patients). Lastly, the CKD-epi formula used to estimate GFR in this study is considered more accurate and less likely to underestimate GFR at higher levels of renal function (≥ 60 mL/ 
